•  
     
     
    Type Size
     

    Changes of Serum Soluble Receptor Activator for Nuclear Factor-κB Ligand after Glucocorticoid Therapy Reflect Regulation of Its Expression by Osteoblasts.

    Serum soluble RANKL and OPG levels were examined in 60 patients with systemic autoimmune diseases receiving glucocorticoid therapy. The authors found that the distribution of serum soluble RANKL was bimodal. It decreased significantly with time in the higher soluble RANKL group and increased significantly with time in the lower soluble RANKL group. Bone mineral density increased in the higher soluble RANKL group with time, but decreased in the lower soluble RANKL group. These results imply that serum soluble RANKL levels may predict changes in bone mass in patients given glucocorticoid therapy for inflammatory disease.

    http://jcem.endojournals.org/content/97/10/E1909.long

    Kaneko K, Kusunoki N, Hasunuma T, Kawai S.